NCT06517823View on ClinicalTrials.gov

Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain

PHASE3CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

April 26, 2024

Primary Completion Date

October 4, 2024

Study Completion Date

October 11, 2024

Conditions
Acute Low-back Pain
Interventions
DRUG

Etoricoxib + Cyanocobalamin fixed dose

One tablet of 90 mg / 0.50 mg a day

DRUG

Etoricoxib fixed dose

One pill of 90 mg a day

Trial Locations (1)

11000

Laboratorio Silanes, S.A. de C.V., Mexico City

All Listed Sponsors
lead

Laboratorios Silanes S.A. de C.V.

INDUSTRY

NCT06517823 - Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain | Biotech Hunter | Biotech Hunter